Affimed Therapeutics, a German therapeutic TandAb antibody company, has reorganised its management team under the leadership of Adi Hoess and Rolf Guenther.
Hoess, previously chief commercial officer, is now chief executive, while Guenther, previously chief executive, is now chief operating officer with a focus on advancing the pipeline through clinical trials.
"With a platform technology allowing development of multiple product candidates it is now time to adapt the organisation to the new needs,’ said Thomas Hecht, chairman of Affimed.
‘I am confident that under the leadership of Adi with his extensive business background in commercial operations and M&A strategies and with Rolf focusing on the clinical development of our core assets and overseeing the operations we have set up the company not only to build on its assets but also to prepare for its future.’
Affimed reorganises management team
Adi Hoess becomes chief executive
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing
Degasser for volatile and aggressive solvents
Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development
Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer
The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies